Halozyme Therapeutics Well-positioned to Execute Existing Strategy With Clear Line of Sight to 10 Approved Products With ENHANZE in 2025 and $1B of Royalty Rev in 2027 >HALO
Halozyme Therapeutics Well-positioned to Execute Existing Strategy With Clear Line of Sight to 10 Approved Products With ENHANZE in 2025 and $1B of Royalty Rev in 2027 >HALO
奧洛茲美醫療已經爲執行現有策略做好了充分準備，清晰地展望到2025年以ENHANZE技術獲批的10個產品，並計劃在2027年實現10億美元的授權收入，超過HALO。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間